Brokerages expect Zealand Pharma A/S (NASDAQ:ZEAL) to report earnings of ($0.36) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Zealand Pharma A/S’s earnings. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Zealand Pharma A/S will report full year earnings of ($1.63) per share for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($1.43) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Zealand Pharma A/S.

Several equities research analysts have issued reports on ZEAL shares. Goldman Sachs Group, Inc. (The) started coverage on shares of Zealand Pharma A/S in a research note on Wednesday, September 27th. They set a “buy” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Zealand Pharma A/S in a research report on Monday, October 16th. Guggenheim assumed coverage on Zealand Pharma A/S in a research report on Tuesday, September 5th. They set a “buy” rating and a $28.00 price objective for the company. Finally, Morgan Stanley started coverage on Zealand Pharma A/S in a research report on Tuesday, September 5th. They set an “overweight” rating and a $28.00 price objective for the company.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/zacks-brokerages-expect-zealand-pharma-as-zeal-to-post-0-36-eps/1679138.html.

Zealand Pharma A/S (NASDAQ ZEAL) traded down $1.15 on Friday, reaching $15.45. 27,245 shares of the company’s stock were exchanged, compared to its average volume of 11,293. Zealand Pharma A/S has a 12 month low of $15.10 and a 12 month high of $20.37.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.